| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 10/19/2004 | US6806084 Comprises dna/lipid carrier complexes for transfection; for modulating the genotype and phenotype into two or more tissues following systemic administration; for gene therapy |
| 10/19/2004 | US6806063 Protein conjugate for use in the treatment of blood disorder |
| 10/19/2004 | US6806061 G protein-coupled receptor gene and methods of use therefor |
| 10/19/2004 | US6806059 Nucleotide sequences coding enzymatic polypeptide for use innthe treatment of asthma, and for use in laundry detergent and stain removers |
| 10/19/2004 | US6805883 Contain cocoa and/or nut procyanidin(s) |
| 10/19/2004 | US6805881 Orally administrable multiple- unit sustained-release dosage forms having controlled agitation- independent release of active compound; erodable hydroxypropyl cellulose |
| 10/19/2004 | US6805878 Transdermal administration of ACE inhibitors |
| 10/19/2004 | US6805862 Generating in subject immune response against ganglioside gd3 by administering antiidiotypic antibody bec-2 (atcc no. hb 10153) |
| 10/19/2004 | US6805854 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
| 10/19/2004 | CA2238574C Targeted cytotoxic anthracycline analogs |
| 10/19/2004 | CA2075454C Melt cocrystallised sorbitol/xylitol compositions |
| 10/17/2004 | CA2463827A1 Methods and compositions for controlled release of bioactive compounds |
| 10/14/2004 | WO2004087931A1 Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof |
| 10/14/2004 | WO2004087768A1 Novel cyclodextrin derivatives, method for the preparation thereof and use thereof for the solubilization of pharmacologically active substances |
| 10/14/2004 | WO2004087765A1 Titanium dioxide complex having molecule distinguishability |
| 10/14/2004 | WO2004087759A2 Method and compositions for conversion of antibody activity |
| 10/14/2004 | WO2004087758A2 Il 13 receptor alpha 2 antibody and methods of use |
| 10/14/2004 | WO2004087740A2 Preserved and stable compositions containing peptide copper complexes and methods related thereto |
| 10/14/2004 | WO2004087739A1 Peg-physiologically active polypeptide homodimer complex having prolonged in vivo half-life and process for the preparation thereof |
| 10/14/2004 | WO2004087684A1 Benzo[1,2,5]oxadiazoles and benzo [1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers |
| 10/14/2004 | WO2004087648A2 Stabilized phenytoin containing composition |
| 10/14/2004 | WO2004087307A1 Chitosan product, method for the production thereof, methods for producing chitosan product derivatives and compositions based thereon |
| 10/14/2004 | WO2004087215A1 Gonadotropin releasing hormone analogues conjugates with steroid hormones |
| 10/14/2004 | WO2004087213A1 Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
| 10/14/2004 | WO2004087178A1 A formulation comprising a bacterial strain |
| 10/14/2004 | WO2004087174A1 Parenteral formulation of mycophenolic acid, a salt or prodrug thereof |
| 10/14/2004 | WO2004087141A1 Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases |
| 10/14/2004 | WO2004087135A1 Oral suspension of tegaserod |
| 10/14/2004 | WO2004087123A1 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| 10/14/2004 | WO2004087121A2 Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases |
| 10/14/2004 | WO2004087117A2 Use of cyclic acetals/ketals for improved penetration of active substances into cells and organs |
| 10/14/2004 | WO2004087114A1 Capsules with delayed release of the capsule contents for oral administration |
| 10/14/2004 | WO2004087108A1 Taste-masking vehicle for coated oxazolidinone particles |
| 10/14/2004 | WO2004087104A1 Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
| 10/14/2004 | WO2004087103A1 Ophthalmic drug delivery system using polymer micell |
| 10/14/2004 | WO2004087101A2 Oral formulations of cladribine |
| 10/14/2004 | WO2004087100A2 Cladribine formulations for improved oral and transmucosal delivery |
| 10/14/2004 | WO2004087071A2 Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection |
| 10/14/2004 | WO2004087052A2 Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent |
| 10/14/2004 | WO2004087045A2 Devices, methods, and compositions to prevent restenosis |
| 10/14/2004 | WO2004087043A2 Stable ophthalmic formulation containing an antibiotic and a corticosteroid |
| 10/14/2004 | WO2004086880A1 Sodium chloride-containing foods and drinks |
| 10/14/2004 | WO2004082658A1 Controlled release system containing saccharose acetate isobutyrate |
| 10/14/2004 | WO2004075811A3 Subcutaneously-administered ganglioside-based vaccine compositions |
| 10/14/2004 | WO2004041245B1 Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases |
| 10/14/2004 | WO2003104282A3 Glycoprotein vi - fc fusion protein for treating vascular disorders |
| 10/14/2004 | WO2003101395A3 Formulations for amylin agonist peptides |
| 10/14/2004 | WO2003031475A8 Antibodies against kdr, their production and uses |
| 10/14/2004 | US20040204566 Chemically-modified G-CSF |
| 10/14/2004 | US20040204565 Use of multivalent chimeric peptide-loaded, MHC/IG molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| 10/14/2004 | US20040204548 polymers comprise particular linkers interposed between a polymer segment and a maleimide group |
| 10/14/2004 | US20040204482 provides a defined blood concentration profile having no rapid initial rise in blood plasma concentration of the good soluble active substance when administered; (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide; nervous system, gastrointestinal, heart disorders, Alzheimer's |
| 10/14/2004 | US20040204479 Injectable composition |
| 10/14/2004 | US20040204474 Hypotensive agents; cardiovascular disorders |
| 10/14/2004 | US20040204441 Nasal delivery of apomorphine |
| 10/14/2004 | US20040204434 Compounds and methods for lowering the abuse potential and extending the duration of action of a drug |
| 10/14/2004 | US20040204399 Aerosolized decongestants for the treatment of sinusitis |
| 10/14/2004 | US20040204395 Water-soluble drugs and methods for their production |
| 10/14/2004 | US20040204391 Applying onto healed wound a composition comprising a fluid, film-forming carrier, and subsequently hardening the carrier into a tangible membrane juxtaposed to the healed wound thereby reducing scarring or improving the appearance thereof |
| 10/14/2004 | US20040204372 Synergistic mixture of piperacillin and tazobactam; controlling bacteria infections |
| 10/14/2004 | US20040204365 Methods of using cyanovirins to inhibit viral infection |
| 10/14/2004 | US20040204364 Peptides for activation and inhibition of deltaPKC |
| 10/14/2004 | US20040204363 providing a complex containing peptide or protein of interest covalently linked to amino terminal ATP binding domain of a heat shock protein 70 (hsp70) or the carboxyl terminal peptide binding domain of an hsp70, contacting the cell with the complex for entry of the complex into the cell |
| 10/14/2004 | US20040204343 Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| 10/14/2004 | US20040203131 diagnosis of transmissible spongiform encephalopathies (TSEs) especially in an immunoassay, as well as its use as an immunogen; genetic engineering |
| 10/14/2004 | US20040203107 Methods and compositions for grafting functional loops into a protein |
| 10/14/2004 | US20040203081 which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure |
| 10/14/2004 | US20040203075 which bind pancreatic beta cells (to secrete insulin) and encapsulate cells for transplantation/treatment of diabetes; solid phase synthesis; kits |
| 10/14/2004 | US20040202737 Process for obtention of decoctions of vitis labrusca and vitis vinifera skins |
| 10/14/2004 | US20040202729 for delivering sulfur containing compounds to skin and absorbing irritants in the skin; high sorption base is employed which comprises non-swelling clay, gum, swelling clay, silicon and combinations thereof; treatment of skin disorders |
| 10/14/2004 | US20040202722 Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
| 10/14/2004 | US20040202720 Delivery of immune response modifier compounds using metal-containing particulate support materials |
| 10/14/2004 | US20040202719 cross-linked polymer encapsulating the therapeutic agent; degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades. |
| 10/14/2004 | US20040202718 compressible controlled release core, swellable polymers one of which is anionic, and an excipient(s) that improves compressibility; an immediate release composition comprising long-acting sulfonyl urea (glimepiride) and controlled release composition comprising biguanide (metformin) |
| 10/14/2004 | US20040202716 Composition |
| 10/14/2004 | US20040202714 Oral pharmaceutical composition |
| 10/14/2004 | US20040202712 Emulsion vehicle for poorly soluble drugs |
| 10/14/2004 | US20040202711 Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia |
| 10/14/2004 | US20040202709 Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery therof |
| 10/14/2004 | US20040202705 including as a permeation enhancer fatty acids, fatty acid esters, fatty alcohols, amides, pyrrolidones, glycerol triesters, and/or terpenes and their salts; provides a huperzine blood plasma level of 0.1 - 30 mg/ml |
| 10/14/2004 | US20040202702 Method and composition for the treatment of scars |
| 10/14/2004 | US20040202696 solid, oil-insoluble active ingredient dispersed in an oily liquid; preferably palatable to animals, exhibits outstanding stability with water-sensitive active ingredients, and is readily accepted by animals |
| 10/14/2004 | US20040202687 Ciprofloxacin formulations and methods of making and using the same |
| 10/14/2004 | US20040202676 using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process |
| 10/14/2004 | US20040202669 Immunogenic compositions containing phospholipid |
| 10/14/2004 | US20040202666 Anti-cancer anthracycline drug-antibody conjugates |
| 10/14/2004 | US20040202646 Bifunctional glycoproteins having a modified carbohydrate complement and their use in tumor-selective therapy |
| 10/14/2004 | US20040202640 Method for topical treatment of scars with rotein Kinase C inhibitors |
| 10/14/2004 | US20040202617 Delivery of opioids through an inhalation route |
| 10/14/2004 | US20040202616 comprises magnesium stearate for improved storage stability; inhalers |
| 10/14/2004 | DE202004012450U1 Delivery unit for administering a medicament into the vaginal cavity of a patient comprises an elongate body with delivery and grip ends, a medicament container, and a piston system |
| 10/14/2004 | DE10315027A1 Kapseln mit verzögerter Freisetzung des Kapselinhaltes zur oralen Verabreichung Sustained-release capsules for oral administration of the capsule content |
| 10/14/2004 | DE10314976A1 Verbesserte Penetration von Wirkstoffen in Zellen und Organe Improved penetration of active substances into cells and organs |
| 10/14/2004 | CA2527130A1 Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
| 10/14/2004 | CA2521250A1 Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases |
| 10/14/2004 | CA2520525A1 Ophthalmic drug delivery system using polymer micelle |
| 10/14/2004 | CA2520406A1 Cxcr4 antagonists and methods of their use |
| 10/14/2004 | CA2520389A1 Method and compositions for conversion of antibody activity |
| 10/14/2004 | CA2520278A1 Benzo[1,2,5]oxadiazoles and benzo [1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers |
| 10/14/2004 | CA2519869A1 Taste-masking vehicle for coated oxazolidinone particles |